Article Text

Download PDFPDF
Ejection fraction: a measure of desperation?
  1. Charlotte H Manisty,
  2. Darrel P Francis
  1. International Centre for Circulatory Health, Imperial College and St Mary’s Hospital, London, UK
  1. Dr C H Manisty, International Centre for Circulatory Health, 59–61 North Wharf Road, London W2 1LA, UK; cmanisty{at}ic.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ejection fraction is the most widely used measure of left ventricular systolic function, but why? It was initially adopted before the introduction of echocardiography, when ventricular function was assessed by ventriculography at cardiac catheterisation. To avoid the huge effort of calibrating ventriculographic volumes, ejection fraction was born as a quick way of quantifying function.

In this edition of Heart, MacIver and Townsend report their findings from a mathematical model that investigates the separated effects of changes to left ventricular (LV) mass and to longitudinal shortening, on ejection fraction (see article on page 446).1 They show that the increased radial wall thickness in LV hypertrophy means that ejection fraction may be preserved despite impaired long-axis shortening. This supports the growing evidence that ejection fraction alone may be an insufficient descriptor of systolic function.

As cardiology is no longer bereft of rapid, calibrated measures of systolic function with the availability of tissue Doppler velocity, strain and strain rate, perhaps we can progress from limiting our assessment to ejection fraction.

Assessment of LV systolic function is used to predict morbidity and mortality,2 in the diagnosis of heart failure, and also to enable or preclude patients from receiving a variety of potentially beneficial procedures including chemotherapy,3 cardioverter-defibrillator …

View Full Text

Footnotes

  • Competing interests: None.

Linked Articles